Magnesium Trisilicate

Identification

Name
Magnesium Trisilicate
Accession Number
DB09281
Type
Small Molecule
Groups
Approved
Description

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Magnesium trisilicate hydrateC2E1CI501T39365-87-2FSBVERYRVPGNGG-UHFFFAOYSA-N
Active Moieties
NameKindUNIICASInChI Key
Magnesium cationionicT6V3LHY83822537-22-0JLVVSXFLKOJNIY-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Alka Phenyl TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralPro Doc Limitee1974-12-311997-08-14Canada
Gasulsol TabMagnesium Trisilicate (130 mg) + Aluminum hydroxide (195 mg)TabletOralHerbes Universelles Inc.1966-12-312009-07-15Canada
GasvaMagnesium Trisilicate (487.5 mg) + Aluminum hydroxide (260 mg)TabletOralLes Produits Gerbex Inc.1970-12-311997-08-11Canada
Gaviscon Regular StrengthMagnesium trisilicate hydrate (14.2 mg/1) + Aluminum hydroxide (80 mg/1)Tablet, chewableOralGlaxo Smith Kline Consumer Heathcare Lp2011-06-13Not applicableUs
Mag-A-folic TabMagnesium Trisilicate (100 mg) + Folic Acid (.4 mg) + Vitamin A (2000 unit)TabletOralMetagenics, Inc.1989-12-311996-10-02Canada
Phenylone Plus TabMagnesium Trisilicate (150 mg) + Aluminum hydroxide (100 mg) + Phenylbutazone (100 mg)TabletOralMedic Laboratory LtÉe1978-12-311996-09-09Canada
R90 Anti-acide TabMagnesium Trisilicate (500 mg) + Calcium Carbonate (300 mg)TabletOralDr Reckeweg Canada1993-12-311997-08-13Canada
Spasmo Nil TabMagnesium Trisilicate (75 mg) + Aluminum hydroxide (75 mg) + Dicyclomine Hydrochloride (2.5 mg) + Dimethicone (7.5 mg)TabletOralDuchesnay Inc.1978-12-312003-07-18Canada
Categories
UNII
FML8G1U0Y3
CAS number
14987-04-3
Weight
Average: 260.857
Monoisotopic: 259.86017997
Chemical Formula
Mg2O8Si3
InChI Key
GXGAKHNRMVGRPK-UHFFFAOYSA-N
InChI
InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4
IUPAC Name
dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate
SMILES
[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O

Pharmacology

Indication

For the treatment of peptic ulcers. Relieving indigestion and heartburn.

Associated Conditions
Pharmacodynamics

Magnesium trisilicate works by increasing the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.

Mechanism of action

The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.

Absorption

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track where, silica can be partly absorbed.

Volume of distribution

The hydrated silicon dioxide formed in the stomach and passes into the intestinal track.

Protein binding

33%

Metabolism
Not Available
Route of elimination

Excreted in the urine.

Half life

16-20 hours

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance.

Toxicity

Adequate doses of magnesium trisilicate may cause diarrhea due to the action of soluble magnesium salts in the enteric tract. Approx 5% of the magnesium is absorbed.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
2,5-Dimethoxy-4-ethylthioamphetamineMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.
3,4-MethylenedioxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.
4-Bromo-2,5-dimethoxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Magnesium Trisilicate.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Magnesium Trisilicate.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Magnesium Trisilicate.
AcepromazineMagnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineMagnesium Trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

General References
  1. Toxnet [Link]
  2. Toxnet [Link]
  3. Sciencedirect [Link]
External Links
KEGG Drug
D03271
PubChem Compound
5311266
PubChem Substance
310265174
ChemSpider
4470779
ChEMBL
CHEMBL2096633
Wikipedia
Magnesium_trisilicate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, chewableOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-2.7ChemAxon
pKa (Strongest Acidic)2.65ChemAxon
pKa (Strongest Basic)-7.7ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area144.84 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity11.36 m3·mol-1ChemAxon
Polarizability11.91 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal silicates. These are inorganic compounds in which the largest oxoanion is silicate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal silicates
Direct Parent
Alkaline earth metal silicates
Alternative Parents
Miscellaneous silicates / Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Silicate / Alkaline earth metal silicate / Inorganic oxide / Inorganic salt / Inorganic metalloid salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 29, 2015 09:58 / Updated on October 01, 2018 16:43